Floatz logo

Low-Dose Can103

Gaucher Disease, Type 3

CANbridge (Suzhou) Bio-pharma Co., Ltd.Phase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Gaucher Disease, Type 3 cohort.

Asset / SponsorPhaseRating
Elelyso
Ari Zimran
Phase 4BB
Cerezyme
Sanofi
Phase 3BB
Eliglustat
Sanofi
Phase 3BB
Venglustat
Sanofi
Phase 3B
Velaglucerase Alfa
Shire
Phase 1/2CCC

View all 10 →

Same molecule, other indications

Low-Dose Can103 is also rated in:

Gaucher Disease, Type 1Dormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →